News

In January this year Novartis had agreed to invest $24m to secure access to chip-in-a-pill technology developed by California-based privately held firm Proteus Biomedical, Reuters reported. The embedded

The winds of change seem fairly constant in the pharmaceutical industry. Complex legislative and regulatory issues, increased competition, complex company structures, and mergers and acquisitions all impact on

As a result of current agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and

BMP Sunstone has posted a net loss of $1.26m for the third quarter 2010, or $0.03 loss per diluted share, compared to net loss of $208,000 or $0.01

The amendment allows UMN to enter into collaboration agreements with Astellas Pharma and IHI Corporation. Astellas’ role will be to support further development, licensure and marketing of PSC’s

BI-204 is a human monoclonal antibody that specifically targets oxidised forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation

AOBO is a pharmaceutical company engaged in improving health through the manufacture, development and commercialisation of prescription and over-the-counter (OTC) products. AOBO has posted a net income of

The clinical results from Flexible Stenting Solutions’ supplementary study conducted in Germany were presented by principle investigator Dierk Scheinert of University of Leipzig – Heart Center. The primary

Nabi initiated this clinical trial in March 2010 and expects to have final data in early 2012. The first clinical trial was initiated in November 2009 and completed